natgillin/translations-raw huggingface dataset:
When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature (2°C to 8°C).
Po pripravi po navodilih so kemijsko in fizikalno obstojnost za uporabo rekonstituiranih raztopin pemetrekseda in raztopin pemetrekseda za infundiranje pokazali za 24 ur v hladilniku (2°C do 8°C).
If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), Pemetrexed Hospira should be withheld until resolution to less than or equal to the patient's pre-therapy value.
Če se pri bolnikih razvijejo nehematološke toksičnosti ≥ stopnje 3 (z izjemo nevrološke toksičnosti), moramo dajanje zdravila Pemetreksed Hospira prekiniti, dokler se vrednosti ne povrnejo na manjše ali enake, kot jih je imel bolnik pred zdravljenjem.
Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver)
Imunsko pogojena hemolitična anemija (propad rdečih krvnih celic, ki ga povzročijo protiteles) Hepatitis (vnetje jeter)
You will always receive Pemetrexed Hospira by infusion into one of your veins.
Zdravilo Pemetreksed Hospira boste vedno prejeli v obliki infuzije v veno.
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Pemetrexed Hospira.
Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Pemetreksed Hospira.
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Hospira has finished.
Cisplatin tudi dajemo v obliki infuzije v veno, približno 30 minut po zaključku infuzije zdravila Pemetreksed Hospira.
• If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may indicate a blood clot in the blood vessels of the lungs).
• Če doživite nenadno težko dihanje, močno bolečino v prsih ali kašelj s krvavim izmečkom (redko) (lahko kaže na krvni strdek v krvnih žilah v pljučih).
To be taken into consideration by patients on a controlled sodium diet.
Ta podatek je treba upoštevati pri bolnikih, ki so na dieti z nadzorovanim vnosom natrija.
A phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fluid demonstrated no difference in pemetrexed dose normalised plasma concentrations or clearance compared to patients without third space fluid collections.
V študiji pemetrekseda so v fazi II pri 31 bolnikih s solidnim tumorjem in stabilno tekočino tretjega prostora pokazali, da ni razlike med normalno koncentracijo v plazmi ali očistkom, doseženo glede na odmerek pemetrekseda, v primerjavi z bolniki brez zaloge tekočine tretjega prostora.
Pemetrexed Hospira must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy.
Zdravilo Pemetreksed Hospira smemo dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije za zdravljenje raka.
Pemetrexed Hospira can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.
Zdravnik vam lahko predpiše zdravilo Pemetreksed Hospira, če imate pljučni rak v napredovalem stadiju in če se vaša bolezen odziva na zdravljenje oz. če po začetni kemoterapiji ostaja večinoma nespremenjena.
However, patients with hepatic impairment, such as bilirubin > 1.5-times the upper limit of normal and/or aminotransferase > 3.0-times the upper limit of normal (hepatic metastases absent) or > 5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied.
Vendar pa bolnikov z okvarjenim delovanjem jeter, ki se kaže kot bilirubin > 1,5-kratnik zgornje meje normalnih vrednosti in/ali aminotransferaza > 3,0-kratnik zgornje meje normalnih vrednosti (brez zasevkov v jetrih) ali > 5,0-kratnik zgornje meje normalnih vrednosti (z zasevki v jetrih), niso posebej preučevali.
Limited clinical data from a separate randomised, Phase-3, controlled trial, suggest that efficacy data (overall survival, progression-free survival) for pemetrexed are similar between patients previously pre-treated with docetaxel (N = 41) and patients who did not receive previous docetaxel treatment (N = 540).
Omejeni klinični podatki iz ločeno randomiziranih, kontroliranih preskušanj faze 3, nakazujejo, da so podatki o učinkovitosti (skupno preživetje, preživetje brez napredovanja) za pemetreksed podobni med bolniki, ki so bili predhodno zdravljeni z doksatakselom (n = 41) in bolniki, ki niso prejeli predhodnega zdravljenja z doksatakselom (n = 540).
Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1,000 micrograms) that you must take once a day while you are taking Pemetrexed Hospira.
Dopolnjevanje vitaminov: zdravnik vam bo predpisal peroralno folno kislino (vitamin) ali multivitaminski pripravek, ki jo vsebuje (350 do 1.000 mikrogramov), ki ga boste morali med prejemanjem zdravila Pemetreksed Hospira jemati enkrat dnevno.
Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson syndrome or toxic epidermal necrolysis).
Obvestite zdravnika, če se pojavijo hud izpuščaj, srbenje ali mehurčki (StevensJohnsonov sindrom ali toksična epidermalna nekroliza).
Pemetrexed Hospira is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.
Pemetreksed Hospira se daje tudi v kombinaciji s cisplatinom, za začetno zdravljenje bolnikov z napredovalim stadijem pljučnega raka.
A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Hospira powder with 9 mg/ml (0.9 %) sodium chloride solution for injection before it is given to you.
Bolnišnični farmacevt, medicinska sestra ali zdravnik bo prašek Pemetreksed Hospira, preden ga boste prejeli, zmešal z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
You will also receive an injection of vitamin B12 (1,000 micrograms) in the week before administration of Pemetrexed Hospira and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed Hospira treatment).
V tednu pred dajanjem zdravila Pemetreksed Hospira boste prejeli tudi injekcijo vitamina B12 (1.000 mikrogramov), nato pa še približno na vsakih 9 tednov (ustrezno 3 ciklusom zdravljenja z zdravilom Pemetreksed Hospira).
Pemetrexed Hospira is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.
Pemetreksed Hospira je namenjen tudi zdravljenju bolnikov z napredovalim stadijem pljučnega raka, katerih bolezen se širi po tem, ko je bila že uporabljena druga začetna kemoterapija.
treatment until disease progression.
Bolniki so prejeli vzdrževalno zdravljenje do napredovanja bolezni.
This should be taken into consideration if you are on a strictly controlled sodium diet.
Ta podatek upoštevajte, če ste na dieti z nadzorovanim vnosom natrija.
Concomitant administration of nephrotoxic drugs (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin) could potentially result in delayed clearance of pemetrexed.
Sočasno dajanje nefrotoksičnih zdravil (denimo, aminoglikozidov, diuretikov zanke, spojin platine, ciklosporina) lahko potencialno povzroči zakasnjeni očistek pemetrekseda.
If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pemetrexed Hospira.
Če ste imeli ali če boste imeli zdravljenje z obsevanjem, prosimo, povejte to zdravniku, saj ob jemanju zdravila Pemetreksed Hospira.lahko pride do zgodnje ali pozne reakcije na obsevanje.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov zdravila Pemetreksed Hospira in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
• If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have fewer platelets than normal which is very common).
• Če vam krvavijo dlesni, krvavite iz nosu ali ustne votline, ali se pojavi kakršnakoli krvavitev, ki se noče ustaviti, rdečkasto ali rožnato obarvan urin, nepričakovane podplutbe (ker imate lahko manj trombocitov, kot je normalno, kar je zelo pogosto).
Chemical and physical in-use stability of reconstituted and infusion solutions of Pemetrexed Hospira powder for concentrate for solution for infusion has been demonstrated for up to 24 hours after reconstitution of the original vial when stored below 25°C.
Rekonstituirane raztopine in raztopine za infundiranje Kemijsko in fizikalno obstojnost za uporabo rekonstituiranih raztopin in raztopin za infundiranje zdravila Pemetreksed Hospira prašek za koncentrat za raztopino za infundiranje so pokazali za 24 ur v hladilniku, po pripravi originalne viale, shranjene pri temperaturi do 25 °C.
Efficacy of pemetrexed vs. docetaxel in NSCLC - ITT population Pemetrexed
Učinkovitost pemetrekseda v primerjavi z docetakselom pri NSCLC - Populacija NZ
Pemetrexed Hospira is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.
Zdravilo Pemetreksed Hospira dajemo v kombinaciji s cisplatinom, drugim zdravilom proti raku, za zdravljenje malignega plevralnega mezotelioma, vrste raka, ki prizadene vrhnjo plast pljuč, bolnikom, ki pred tem še niso prejemali kemoterapije.
Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.
Pemetreksed je večtarčno protirakavo antifolatno zdravilo, ki deluje s porušenjem ključnih presnovnih procesov, odvisnih od folata, ki so nujni za podvajanje celic.
Pemetrexed Hospira 100 mg contains less than 1 mmol (23 mg) of sodium i.e. essentially ‘sodium free'.
Pemetreksed Hospira 100 mg vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni "brez natrija".
For instructions on reconstitution and dilution of Pemetrexed Hospira before administration, see section 6.6
Za informacije o rekonstituciji in redčenju zdravila Pemetreksed Hospira pred uporabo glejte poglavje 6.6.
The other ingredients are mannitol (E421), hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH adjustment).
Pomožne snovi so manitol (E421), klorovodikova kislina (za uravanavanje pH) in natrijev hidroksid (za uravnavanje pH).
Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.
Redkeje opaženi učinki so Stevens- Johnsonov sindrom in toksična epidermalna nekroliza.
Randomised and treated patients Fully supplemented patients
Randomizirani in zdravljeni bolniki
Gemcitabine + Cisplatin
Prednost pvrednost pemetreksed + cisplatin gemcitabin + cisplatin
Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chlorideand polyolefin- lined administration sets and infusion bags.
Raztopine pemetrekseda za infundiranje, pripravljene, kot je navedeno zgoraj, so skladne s seti za dajanje in infuzijskimi vrečkami iz polivinilklorida in prevlečenimi s poliolefinom.
Pemetrexed*** (N = 800)
Dogodek** Pemetreksed*** (N = 800)
Further dilution by a healthcare provider is required prior to administration.
Pred dajanjem mora zdravstveni delavec raztopino še dodatno razredčiti.
Dose of Pemetrexed Hospira (mg/m2)
Odmerek zdravila Pemetreksed Hospira (mg/m
You must contact your doctor immediately if you notice any of the following:
Če opazite katerega od spodaj naštetih učinkov, morate nemudoma poklicati zdravnika:
You must take at least 5 doses during the seven days before the first dose of Pemetrexed Hospira.
V sedmih dneh pred prvim odmerkom zdravilom Pemetreksed Hospira morate vzeti vsaj 5 odmerkov.
Each pack contains one vial of 100 mg, 500 mg or 1,000 mg pemetrexed as (pemetrexed disodium hemipentahydrate).
Vsako pakiranje vsebuje eno vialo s 100 mg, 500 mg ali 1.000 mg pemetrekseda (v obliki dinatrijevega pemetrekseda hemipentahidrata).
Pemetrexed Hospira should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Zdravilo Pemetreksed Hospira se daje kot 10-minutna intravenska infuzija prvi dan vsakega 21dnevnega ciklusa.
Leucocytes decreased 53.0 Haemoglobin decreased 26.2 Platelets decreased
Znižani levkociti 53,0 Znižan hemoglobin Znižani trombociti
Not known (frequency cannot be estimated from the available data)
Neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) Otekanje spodnjih okončin z bolečino in pordelostjo Povečano izločanje urina
Gemcitabine/Cisplatin (N = 830)
Gemcitabin/cisplatin (N = 830)
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (N = 399, 9.3 versus 8.0 months, adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (N =172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018).
Analiza vpliva histologije NSCLC glede učinka zdravljenja na skupno preživetje je bila prednostna za pemetreksed proti docetakselu pri tistih, ki nimajo pretežno luskaste histologije (n = 399, 9,3 proti 8,0 mesecev, prilagojen RT = 0,78; 95 % IZ = 0,61-1,00, p = 0,047) in je bila prednostna za docetaksel za luskasto celično histologijo karcinoma (n = 172, 6,2 proti 7,4 mesecev, prilagojen RT = 1,56; 95 % IZ = 1,082,26, p = 0,018).
• HR (95% CI)
• RT (95% IZ)
Dose modification table for Pemetrexed Hospira (as single agent or in combination) and cisplatin - Non-haematologic toxicities a, b
Preglednica 2 - Preglednica za prilagajanje odmerkov zdravila Pemetreksed Hospira (kot edine učinkovine ali v kombinaciji) in cisplatina - Nehematološke toksičnosti a, b
Excipients: mannitol, hydrochloric acid concentrated, sodium hydroxide (see package leaflet for further information)
Pomožne snovi: manitol, koncentrirana klorovodikova kislina, natrijev hidroksid (Opozorila so navedena v navodilu za uporabo).
A multi-centre, randomised, open-label, Phase-3 study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed plus cisplatin (Intent-To-Treat [ITT] population N = 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT N = 863) in overall survival (adjusted hazard ratio (HR) 0.94; 95% CI= 0.84-1.05).
Multicentrična, randomizirana, odprta študija faze 3 pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri bolnikih, ki v preteklosti še niso prejemali kemoterapije, z lokalno napredovalim ali metastatskim (stopnja IIIb ali IV) nedrobnoceličnim karcinomom pljuč (NSCLC), je pokazala, da je pemetreksed skupaj s cisplatinom (Populacija z namenom zdraviti, [NZ] populacija N = 862) dosegla prvotno končno točko in pokazala podobno klinično učinkovitost, kot gemcitabin skupaj s cisplatinom (NZ N = 863) v skupnem preživetju (prilagojeno razmerje tveganja 0,94; 95 % IZ = 0,84-1,05).
Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma
Učinkovitost pemetrekseda skupaj s cisplatinom v primerjavi s cisplatinom pri malignem plevralnem mezoteliomu
How to use Pemetrexed Hospira
Kako uporabljati zdravilo Pemetreksed Hospira
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95% CI=0.64-0.96, p=0.0195).
Po indukcijskem zdravljenju s pemetreksedom skupaj s cisplatinom (4 cikli) je bilo zdravljenje s pemetreksedom statistično boljše od placeba glede skupnega preživetja (mediana 13,9 mesecev v primerjavi z 11,0 meseci, razmerje tveganja = 0,78, 95 % IZ=0,64-0,96, p=0,0195).
Pemetrexed Hospira contains sodium
Pemetreksed Hospira vsebuje natrij
The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.
Ustrezno prostornino rekonstituirane raztopine pemetrekseda moramo še nadalje redčiti do 100 ml z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje brez konzervansa; damo jo kot intravensko infuzijo, ki teče 10 minut.
Type I glass vial with rubber stopper containing 100 mg, 500 mg or 1,000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
Steklena viala tipa I z gumijasto zaporko, ki vsebuje 100 mg, 500 mg ali 1.000 mg pemetrekseda ( v obliki dinatrijevega pemetrekseda hemipentahidrata).
Dose modification table for Pemetrexed Hospira (as single agent or in combination) and cisplatin - Neurotoxicity
Preglednica 3 - Preglednica za prilagajanje odmerkov zdravila Pemetreksed Hospira (kot edine učinkovine ali v kombinaciji) in cisplatina - Nevrotoksičnost
75% of previous dose (both Pemetrexed
75 % predhodnega odmerka (obeh - zdravila Pemetreksed Hospira in cisplatina)
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5% of 800 patients randomly assigned to receive single-agent pemetrexed and 402 patients randomly assigned to receive placebo in the single-agent pemetrexed maintenance (JMEN: N= 663) and continuation pemetrexed maintenance (PARAMOUNT: N=539) studies.
Spodnja preglednica podaja pogostnost in izraženost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri > 5 % od 800 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali pemetreksed kot edino zdravilo, in 402 bolnikov, ki so naključno prejemali placebo v študijah vzdrževalnega zdravljenja samo s pemetreksedom (JMEN: N=663) ter nadaljevalnega zdravljenja s pemetreksedom (PARAMOUNT: N=539).
Pemetrexed Hospira is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section
Zdravilo Pemetreksed Hospira je indicirano kot monoterapija za zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega karcinoma, ki nima pretežno ploščatocelične histologije pri bolnikih, pri katerih bolezen ni napredovala neposredno po kemoterapiji na osnovi platine (glejte poglavje 5.1).
JMEN: Kaplan-Meier plots of progression-free survival (PFS) and overall survival pemetrexed versus placebo in patients with NSCLC other than predominantly squamous cell histology
JMEN: Kaplan Meier-jeva grafa preživetja brez napredovanja in skupnega preživetja za pemetreksed v primerjavi s placebom pri bolnikih z NSCLC, ki nima pretežno ploščatocelične histologije:
The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5% of 839 patients with NSCLC who were randomised to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomised to receive cisplatin and gemcitabine.
Spodnja preglednica podaja pogostnost in resnost neželenih učinkov, ki so jih ocenili kot možno povezane s študijskim zdravilom, o katerih so poročali pri > 5 % od 839 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in pemetreksed in 830 bolnikov z nedrobnoceličnim karcinomom pljuč, ki so naključno prejemali cisplatin in gemcitabin.
The recommended dose of Pemetrexed Hospira is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Zdravilo Pemetreksed Hospira v kombinaciji s cisplatinom Priporočeni odmerek zdravila Pemetreksed Hospira je 500 mg/m2 telesne površine (TP), dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
EXP Read the package leaflet for the shelf life of the reconstituted product.
EXP Za informacije o roku uporabnosti rekonstituiranega zdravila preberite navodilo za uporabo.
After reconstitution as directed, the solution contains 25 mg/ml of pemetrexed.
Po rekonstituciji po navodilu vsebuje raztopina 25 mg/ml pemetrekseda.
The median OS for the overall population (N = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI= 0.65-0.95, p = 0.01192).
Mediana skupnega preživetja za celotno populacijo (N = 663) je bila 13,4 mesece za skupino s pemetreksedom in 10,6 mesecev za skupino s placebom, razmerje tveganja = 0,79 (95 % CI: 0,65 do 0,95; p = 0,01192).
Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer's Injection and Ringer's Injection.
Pemetreksed je inkompatibilen z vehikli, ki vsebujejo kalcij, vključno z raztopino Ringerjevega laktata za injiciranje in Ringerjevo raztopino za injiciranje.
What Pemetrexed Hospira looks like and contents of the pack Pemetrexed Hospira is a powder for concentrate for solution for infusion in a glass vial.
Pemetreksed je prašek za koncentrat za raztopino za infundiranje v stekleni viali.
Pemetrexed Hospira in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Zdravilo Pemetreksed Hospira je v kombinaciji s cisplatinom indicirano kot zdravljenje prvega izbora za bolnike z lokalno napredovalim ali metastatskim nedrobnoceličnim karcinomom pljuč, ki nima pretežno ploščatocelične histologije (glejte poglavje 5.1).
Dose modification table for Pemetrexed Hospira (as single agent or in combination) and cisplatin - Haematologic toxicities Nadir ANC < 500/mm3 and nadir platelets ≥ 50,000/mm3
Preglednica 1 - Preglednica za prilagajanje odmerkov zdravila Pemetreksed Hospira (kot edine učinkovine ali v kombinaciji) in cisplatina - Hematološke toksičnosti Najnižji ANC < 500/mm
You must continue taking the folic acid for 21 days after the last dose of Pemetrexed Hospira.
Po zadnjem odmerku zdravila Pemetreksed Hospira morate še 21 dni jemati folno kislino.
Pemetrexed Hospira 100 mg powder for concentrate for solution for infusion Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion Pemetrexed Hospira 1,000 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Hospira 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 500 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 1.000 mg prašek za koncentrat za raztopino za infundiranje
*** According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.
*** V skladu z CTC Nacionalnega inštituta za rakava obolenja (v2.0; NCI 1998), motnje okusa in alopecija morata biti poročana kot stopnja 1 ali 2.
PHARMACEUTICAL FORM AND CONTENTS Powder for concentrate for solution for infusion 1 vial
Prašek za koncentrat za raztopino za infundiranje 1 viala
Pemetrexed Hospira in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Zdravilo Pemetreksed Hospira je v kombinaciji s cisplatinom indicirano za zdravljenje bolnikov z neresektabilnim malignim plevralnim mezoteliomom, ki jih še nismo zdravili s kemoterapijo.
Pemetrexed Hospira 1,000 mg vials contain approximately 108 mg sodium per vial.
Pemetreksed Hospira 1.000 mg vsebuje približno 108 mg natrija na vialo.
Each 100 mg vial contains approximately 11 mg sodium.
Pomožna snov z znanim učinkom Ena 100 mg viala vsebuje približno 11 mg natrija.